Introduction
Rheumatoid Arthritis (RA) is the most common chronic autoimmune disease that results in systemic inflammation and primarily attacks synovial joints [1, 2] . RA is associated with significant mortality and morbidity, including diminished health related quality of life, cognitive dysfunction and work disability [3] [4] [5] .
The treatment paradigm for RA has changed dramatically over the last two decades, with more effective interventions introduced to prevent joint damage and functional impairment. Treatments for RA rest on use of disease-modifying antirheumatic drugs (DMARDS) including conventional synthetic DMARDs, biological DMARDS and targeted synthetic DMARDS [6] [7] [8] .The potent therapeutic interventions enable targeting specific components of the immune system, which in turn allows efficient suppression of the pathologic inflammation cascade which causes joint destruction. On the other hand, treatment with biologics leaves the patient more susceptible to infection by inducing a certain extent of immuno-suppression [9] .
European League Against Rheumatism (EULAR) and the American College Rheumatology (ACR) have evidencedriven recommendations for the use of pharmacotherapies, weighing the risk-benefits of the pharmacotherapies; a key recommendation that consistently found its place in the EULAR/ACR guidelines in the recent years is to initiate appropriate therapy soon after diagnosis in order to achieve clinical remission (preferred), or low disease activity [6] [7] [8] 10, 11] .As clinical practices in the US and Europe adopt the EULAR/ACR guidelines/recommendations, the extent to which patients who were managed towards remission were in fact maintained in remission and what their clinical characteristics were in the respective geographies is unknown. This study objective was to address this evidence gap in portraying the characteristics of RA patients in Europe and the United States (US) in disease remission, per physician's clinical assessment/judgment.
Material and Methods
The study was a multi-country, multi-center retrospective medical chart review of adult (16-89 years old) RA patients conducted among physicians in the US and big-5 European countries (5EU), namely, the United Kingdom (UK), France, Germany, Italy and Spain. Physicians (mainly, rheumatologists)were sampled in each of the countries using online physician panels to attain a geographically representative sample in the respective countries. Invitations to participate in the research were sent to a random set of physicians in the existing online physician panels. The physicians representing both hospital-based and private practices in each country, personally responsible for choosing and prescribing treatment for patients with RA, and treating a minimum of 2RA patients per week and having 3-30 years of clinical practice experience were screened for study participation. Each physician reported de-identified anonymous data on patients who were recently treated with a biologic as part of usual care. Up to 5study-eligible RA patient charts were randomly selected by each physician from a sample of prospective patients visiting their respective center/practice during the study screening period in OctDec 2011.
The electronic data collection form was used to collect the following data elements from eligible patient charts: patient demographics, laboratory values, treatment patterns/dynamics andppatient symptomatology/disease status. Erythrocyte sedimentation rate (ESR, mm/h), C- 
Results
Overall, data corresponding to 1566 eligible RA patients (5EU: 1161, US: 405) who were in disease remission (per physician assessment) at the time of the study were included in the study. Mean age of these RA patients were 51.6 years and 51.9 years in the 5EU and US respectively; 70.1% and 72.3% were female in 5EU and US respectively. At the time of the study, the average duration of remission for RA patients in 5EU and US was 12.2 months (range: 7.5 months (Italy) -14.8 months (UK))) and 12.1 months respectively.
Majority of these patients, specifically, 75% in 5EU and 74% in the US were on their 1st line biologics, while 20% and 22% were respectively on 2 nd line biologics in EU5 and the US [ Table 1 ].The average duration of remission was similar among the patients on 1 st line biologics (5EU: 12.3 months (range: 7.3 months (Italy) -15.0 (France))); US: 12.7 months); patients on 2 nd line biologics in the 5EU on average had a slightly longer duration of remission (12.1 months; range: 8.6 months (Italy) -16.3 months (UK)) in comparison to their US counterparts (11.3 months). 
Discussion
The evolving paradigm of RA patient management involves a multi-dimensional approach encompassing an early diagnosis of the disease and initiation of potent pharmacotherapy, while setting appropriate patientspecific treatment target and applying tight control and relevant therapeutic adaptations to reach this target. EULAR and ACR consistently advocated for clinical remission or low disease activity as key treatment targets [6] [7] [8] [10] [11] [12] . Treat-to-Target recommendations have historically been non-prescriptive (in terms of pharmacotherapies) and have recommended certain modalities of care delivery and advocated for the general principle of achieving the end target of disease remission or low disease activity [10] . This was the case at the time this study was conducted (in 2011). In this context, the results of this study reporting similar characteristics of RA patients in remission in 5EU and the US, as well as the association of low disease activity consistently observed across these patient cohorts (as measured via validated/standard disease assessment scores) is a significant finding. This depicts the potential influence of EULAR/ACR (in standardizing Treat-to-Target The mean duration of remission among the US cohort was similar to that of the 5EU averages in this study; however, the duration of remission varied within 5EU depending on the country, with patients in Italy having a lower duration of remission in both 1 st and 2 nd line treatments. These observed variations may have been influenced by the time since the patient was initiated on the concerned line of therapy (thus, if patients were on a given treatment line for a shorter duration at the time of study data collection, the duration of remission is likely to be shorter).
Although physicians were randomly recruited for this study, the findings may represent only the participating physician practices, and may vary from those of nonparticipating physician practices. This study did not assess the adherence to different facets of Treat-to-Target guidelines in relation to other modalities of RA disease management or care delivery.
Conclusion
In summary, this is one of the first studies to compare RA patients in remission in the 5EU and US. The characteristics of RA patients in remission in this study were found mostly similar between these geographic clusters, despite the potential variations in healthcare systems and modalities of care delivery. This could be possibly attributed to EULAR/ACR efforts in standardizing the Treat-to-Target guidelines with a focus on clinical remission. There were some variations in duration of disease remission observed within the 5EU, which may warrant scrutiny.
